University of Maryland researchers found that AlphaFold 2 is ineffective for drug design as it clashes with a widely used cancer drug, while the AF2RAVE method aligns accurately with the drug's experimental pose.
University of Maryland researchers found that AlphaFold 2 is ineffective for drug design as it clashes with a widely used cancer drug, while the AF2RAVE method aligns accurately with the drug's experimental pose.
Tyler O'Neal, Staff Editor SCIENCE

University of Maryland makes dubious claims about its new AF2RAVE drug discovery method

In a recent article published by the University of Maryland, scientists claimed that their newly developed AF2RAVE method is more effective than Google's AlphaFold 2 technology in the field of drug discovery. This groundbreaking method combines AlphaFold's AI prediction capabilities with physics-based simulations and aims to expedite the drug discovery process.

However, the claims made in the article raise skepticism and prompt a critical evaluation of the AF2RAVE approach. One key criticism is the lack of comprehensive data and independent validation of its performance. While the researchers emphasize a success rate of over 50% in matching drug candidates with existing drugs targeting specific protein shapes, the absence of detailed statistics and studies raises concerns about the credibility of their findings.

The skepticism surrounding the AF2RAVE method also stems from the challenges of predicting protein structures, especially non-native conformations. The complex nature of protein folding and the uncertainties in computational modeling raise questions about the feasibility of accurately predicting protein configurations solely based on AI and physics-based simulations.

Moreover, the competitive landscape of AI-driven drug discovery raises questions about the motivations behind such bold assertions and the potential impact on scientific integrity and public trust in cutting-edge research.

In conclusion, while the AF2RAVE method holds promise as a novel approach to drug discovery, rigorous validation, transparent reporting of results, and independent assessments are crucial to validating its efficacy and reliability. As the scientific community continues to explore the intersection of AI and physics in healthcare innovation, a critical and balanced evaluation of such claims is imperative to ensure meaningful progress in the field of drug discovery.

Intel suspends dividend, cuts 15,000 jobs, reports dismal earnings results

Tyler O'Neal, Staff Editor SCIENCE

Today, Intel Corporation announced its financial results for the second quarter of 2024, shedding light on significant developments and concerns within the Data Center and AI (DCAI) sector. The report revealed a 3% decrease in DCAI sales, amounting to $3.0 billion, which has sparked worry within the industry.

The second-quarter revenue was $12.8 billion, a 1% decrease compared to the previous year. Additionally, the GAAP earnings (loss) per share (EPS) attributable to Intel came in at $(0.38). Despite these disappointing figures, Intel remains committed to a competitive dividend as cash flows improve.

CEO Pat Gelsinger expressed concern, stating, "Our Q2 financial performance was disappointing, even as we hit key product and process technology milestones. Second-half trends are more challenging than we previously expected, and we are leveraging our new operating model to take decisive actions that will improve operating and capital efficiencies while accelerating our IDM 2.0 transformation."

The heart of the matter lies in the decreased sales experienced by the DCAI sector, with revenue dropping by 3% in the second quarter of 2024. This downtrend is a cause for concern among stakeholders and industry experts, as it may signify broader challenges within the AI and data center sphere.

According to David Zinsner, Intel CFO, "Second-quarter results were impacted by gross margin headwinds from the accelerated ramp of our AI PC product, higher than typical charges related to non-core businesses, and the impact from unused capacity. By implementing our spending reductions, we are taking proactive steps to improve our profits and strengthen our balance sheet."

The company is implementing a comprehensive reduction in spending, including a more than 15% headcount reduction, to resize and refocus. These initiatives aim to create a sustainable financial engine and accelerate profitable growth, amidst the challenges posed by the decreased sales within the DCAI sector.

It is imperative to analyze and address the underlying factors contributing to the decline in DCAI sales. This necessitates a diverse array of perspectives, extending from industry analysts to company stakeholders, to comprehensively understand the implications of Intel's report and chart a path forward for the DCAI sector.

The future holds promising milestones, including the launch of Intel 18A next year to regain process technology leadership. These endeavors signify Intel's commitment to strengthening its position in the market, improving profitability, and creating shareholder value despite the challenges faced in the DCAI sector.

The 3% decrease in DCAI sales is a red flag that cannot be overlooked. It is within this context that Intel's financial results warrant a critical examination, necessitating collaborative efforts to navigate the path ahead for the DCAI sector and the company as a whole.

In conclusion, Intel's second-quarter 2024 financial results signal a concerning decline in DCAI sales, prompting introspection and strategic deliberation within the industry. As stakeholders and observers scrutinize the report, a multi-faceted approach is imperative to discern the underlying challenges and chart a course toward revitalizing the DCAI sector.

Lattice survives a sharp sales decline

Tyler O'Neal, Staff Editor SCIENCE

The latest financial results released by Lattice Semiconductor Corporation paint a grim picture for the future as the company grapples with a significant decline in sales. The second quarter of 2024 has recorded a revenue of $124.1 million, marking an alarming 34.7% decrease from the previous quarter and a worrying 55.3% drop from the same period last year. This continuous downward trend in sales has raised concerns about the company's ability to navigate through increasingly challenging market conditions.

The company's Interim Chief Executive Officer, Esam Elashmawi, pointed to the prevailing industry headwinds that have taken a toll on Lattice Semiconductor's performance. While acknowledging the turbulent nature of the semiconductor sector, there seems to be little room for optimism as the effects of inventory normalization continue to weigh heavily on the company's bottom line. Despite efforts to expand the product portfolio and position the company for long-term growth, the harsh reality of declining sales remains a glaring obstacle.

Furthermore, the financial outlook for the third quarter of 2024 does not offer much solace to investors and stakeholders. With anticipated revenues between $117 million and $137 million, Lattice Semiconductor is facing an uphill battle to reverse the downward trajectory of sales. The expected gross margin percentage of 69.0% with an additional 1% on a non-GAAP basis adds another layer of uncertainty to the company's financial stability. The daunting challenge of managing total operating expenses in the range of $53 million to $55 million further underscores the delicate financial position that Lattice Semiconductor finds itself in.

In conclusion, the dismal second-quarter results and the grim outlook for the future raise serious doubts about Lattice Semiconductor's ability to weather the storm of declining sales. With market conditions becoming increasingly volatile and competition intensifying, the road ahead appears fraught with challenges for the once-prominent semiconductor company. Investors and industry analysts are left pondering whether Lattice Semiconductor will be able to reverse its fortunes and regain its foothold in the highly competitive market landscape.